New hope for advanced breast cancer patients who run out of options
NCT ID NCT07393321
Summary
This study is testing if adding a new experimental drug called NTQ1062 to a standard hormone therapy (fulvestrant) works better than the standard therapy alone. It is for people with a specific type of advanced breast cancer that has stopped responding to previous hormone treatments. The main goal is to see if the new combination can slow down the cancer's growth for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.